The GLP-1 discovery and development of its agonists have revolutionized biomedical research focusing on metabolic disorders, such as obesity, T2DM, atherosclerosis and cardiovascular diseases (CVDs) and pharmaceutical industrial revenue. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.